INTRODUCTION MODE FOR NITROCATECHOLS Russian patent published in 2017 - IPC A61K31/4439 A61P25/00 A61P25/16 

FIELD: pharmacology.

SUBSTANCE: method of prevention or treatment of a disorder of the central and peripheral nervous system, comprising administration of a therapeutically effective amount of 5-[3-(2,5-dichloro-4,6-dimethyl-1-hydroxypyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol compound or pharmacologically acceptable salts, esters, carbamates and phosphates thereof in combination with catecholamine levodopa drug to a patient suffering from the said disorder, in the form of a single daily dose at least for an hour or an hour after the last daily dose of levodopa. A method for prevention or treatment of a disorder of the central and peripheral nervous system, comprising administration of a therapeutically effective amount of 5-[3-(2,5-dichloro-4,6-dimethyl-1-hydroxypyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol compound or pharmacologically acceptable salts, esters, carbamates and phosphates to a patient suffering from the said disorder without food and/or between meals. A method for prevention or treatment of a disorder of the central and peripheral nervous system, comprising administration of a therapeutically effective amount of 5-[3-(2,5-dichloro-4,6-dimethyl-1-hydroxypyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol compound or pharmacologically acceptable salts, esters, carbamates and phosphates thereof, in combination with catecholamine levodopa drug to a patient suffering from the said disorder, wherein the said compound is administered once a day at least 1 hour after the introduction of the last daily dose of levodopa, and less than 90 minutes before going to bed, or upon sleep time occurrence. A method for Parkinson's disease prevention or treatment, comprising administration of a therapeutically effective amount of 5-[3-(2,5-dichloro-4,6-dimethyl-1-hydroxypyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol compound or pharmacologically acceptable salts, esters, carbamates and phosphates thereof, in combination with catecholamine levodopa drug to a patient suffering the from said disease, wherein the said compound is administered once daily at least 1 hour after administration of the last daily dose of catecholamine drug and less than 90 minutes before going to bed, or at the onset of sleep time and at least 1 hour after the last meal and at least 1 hour before the next meal.

EFFECT: methods are effective for prevention or treatment of disorders of the central and peripheral nervous system.

19 cl, 3 dwg, 4 tbl, 3 ex